← Oncology Approval Tracker

FDA DECISION ·

Keytruda + gemcitabine + cisplatin

pembrolizumab + gemcitabine + cisplatin · Merck

FDA approvalNew or expanded indicationBiliary tract cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For locally advanced unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin.

LAMPGEN ANALYSIS

Why it matters

The decision added a checkpoint inhibitor to a chemotherapy backbone for advanced biliary tract cancer.

What research teams should watch

Capture the primary biliary site, extent of disease and chemotherapy readiness when matching patients to the evidence.

PRIMARY RECORDS

Sources